Su1018 - Direct Healthcare Cost Analysis of Inflammatroy Bowel Disease in South Korea

2018 ◽  
Vol 154 (6) ◽  
pp. S-456
Author(s):  
Jooyoung Lee ◽  
Jihye Kim ◽  
Eun Ae Kang ◽  
hyun jung lee ◽  
Jaeyoung Chun ◽  
...  
Keyword(s):  
Cost Analysis ◽  
South Korea ◽  
Healthcare Cost ◽  
Bowel Disease ◽  
Direct Healthcare Cost

scholarly journals A direct healthcare cost analysis of the cryopreserved versus fresh transfer policy at the blastocyst stage

2017 ◽  
Vol 34 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Enrico Papaleo ◽  
Luca Pagliardini ◽  
Valeria Stella Vanni ◽  
Diana Delprato ◽  
Patrizia Rubino ◽  
...  
Keyword(s):  
Cost Analysis ◽  
Healthcare Cost ◽  
Blastocyst Stage ◽  
Direct Healthcare Cost ◽  
Transfer Policy ◽  
Fresh Transfer

Direct Healthcare Cost Analysis of Endoscopic Compared with Sublabial Transseptal Pituitary Surgery

2012 ◽  
Vol 73 (S 01) ◽  
Author(s):  
Candace Mitchell ◽  
Adam Zanation ◽  
Brent Senior ◽  
Matthew Ewend ◽  
Charles Ebert
Keyword(s):  
Cost Analysis ◽  
Healthcare Cost ◽  
Pituitary Surgery ◽  
Direct Healthcare Cost

scholarly journals Healthcare Cost of Stargardt Disease

2020 ◽  
Author(s):  
Kanza Aziz ◽  
Bonnielin K. Swenor ◽  
Joseph K. Canner ◽  
Mandeep S. Singh
Keyword(s):  
Macular Degeneration ◽  
Healthcare Cost ◽  
Financial Burden ◽  
Age Related Macular Degeneration ◽  
Administrative Claims ◽  
Direct Healthcare Cost ◽  
Stargardt Disease ◽  
Cross Sectional ◽  
Patient Cost ◽  
Age Related

AbstractImportanceStargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail.ObjectiveTo estimate the direct healthcare cost of SD.DesignCross-sectional analysis of healthcare claims.ParticipantsPatients with an ICD-9 diagnosis code of SD, non-exudative age-related macular degeneration (AMD), or bilateral sensorineural hearing loss (SHL).MethodsOutpatient administrative claims data from the IBM® MarketScan® Commercial Claims and Encounters Database from 2010 to 2014 were analyzed.Main Outcome MeasureAnnual per-patient direct healthcare cost.ResultsA total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD patients respectively). The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71) was higher than that of SHL (median: $51.01, IQR: $25.66-$121.66, p <0.001) and AMD (median: $76.20, IQR: $38.00-$164.86, p <0.001). When adjusted for covariates, the annual payment for SD was $47.83 higher than SHL (p<0.001) and $17.34 higher than AMD (p<0.001).Conclusions and RelevanceThere is a significant direct healthcare cost associated with SD. The annual per-patient cost of SD was higher than SHL, another condition that causes sensory impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of nonexudative AMD.

Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation

2006 ◽  
Vol 131 (3) ◽  
pp. 719-728 ◽  
Author(s):  
Selwyn Odes ◽  
Hillel Vardi ◽  
Michael Friger ◽  
Frank Wolters ◽  
Maurice G. Russel ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Cost Analysis ◽  
Bowel Disease ◽  
Inception Cohort ◽  
Inflammatory Bowel

Direct healthcare cost of schizophrenia – European overview

2018 ◽  
Vol 48 (1) ◽  
pp. 79-92 ◽  
Author(s):  
G. Kovács ◽  
T. Almási ◽  
A. Millier ◽  
M. Toumi ◽  
M. Horváth ◽  
...  
Keyword(s):  
Healthcare System ◽  
Healthcare Cost ◽  
Direct Healthcare Cost ◽  
Antipsychotic Therapy ◽  
Substantial Impact ◽  
Cochrane Database ◽  
Specific Symptoms ◽  
The Impact ◽  
Pharmaceutical Prices ◽  
Working Out

AbstractPurposeTo provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs.MethodsStudies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017.ResultsTwenty-three studies, from the 1075 references initially identified, were included in this review. The annual cost per patient ranged from €533 in Ukraine to €13,704 in the Netherlands. Notably drug costs contributed to less than 25% of the direct healthcare cost per patient in every country, which might be explained by similar pharmaceutical prices among countries due to the reference pricing system applied in Europe. Inpatient costs were the largest component of health service costs in the majority of the countries. Despite methodological heterogeneity across studies, four major themes could be identified (age, severity of symptoms, continuation of treatment/persistence, hospitalization) that have substantial impact on the costs of schizophrenia.ConclusionsSchizophrenia represents a substantial cost for the healthcare system in Europe driven by the high cost per patient. Substantial savings could potentially be achieved by increasing investment in the following areas: (1) reducing the number of hospitalizations e.g. by increasing the efficiency of outpatient care; (2) working out interventions targeted at specific symptoms; (3) improving patient persistence and adherence in antipsychotic therapy.

Sign in / Sign up

Export Citation Format

Share Document